Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-12-09 00:00:00 ET · period of report 2025-12-05 · accession 0002001011-25-000123 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-09 | 2025-12-05 | LGND | Espinoza Octavio | CFO | F - Tax | $184.87 | -1,862 | 28.0K | -6% | -$344.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-05 | F | D | 1,862 | $184.87 | 27,990 | D | — | — | (F1) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |